NIH Recombinant DNA Advisory Committee
Executive Summary
Will meet June 9 and 10 at the National Institutes of Health in Building 31C, Conference Room 6 at 9 a.m. Items to be discussed include a clinical trial to assess safety, efficacy, and cost of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis, a Phase I trial testing genetically engineered interleukin-7 melanoma vaccine, and a Phase I study examining injection of glioblastoma patients with tumor cells genetically modified to secrete IL-2
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth